May 13, 2021 at 6:16AM
Cathie Wood has gained notoriety from making some seemingly outlandish calls on stocks and for being right. Her company s extrapolation of real world data and technological trends has proved to be an incredibly profitable investing strategy, even after some recent turbulence.
One of her less controversial projections is around preventative cancer screening. Specifically, she and her team believe liquid-biopsy screening for cancer could grow to a $150 billion market as the cost of tests drop.
The thinking is that early screening is the best way to save lives, since all solid tumors progress from treatable and local to lethal and metastatic. The falling cost of sequencing the human genome has introduced many new use cases, and the U.S. health system will likely adopt routine screening as costs drop below $1,000. If the projection proves true, three of her portfolio s companies
Crystal Cox/Insider; Precigen; Mark Neuling/CNBC/NBCU Photo Bank/NBCUniversal via Getty Image; Marianne Ayala/Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Insider found the highest-paid CEOs in the drug industry.
We analyzed CEO pay in 2020 at nearly 200 pharma and biotech companies.
Here are the 17 CEOs who made the most, led by Regeneron, Guardant Health, and Royalty Pharma.
The biotech industry is booming, and its success translated in 2020 into large paychecks for CEOs.
The industry saw in the past year historic highs in terms of cash raised, companies going public, and actual impact on the world.
Pandemic Boosts Diagnostics Field with High Revenues and Acquisitions
20/04/2021 - 5 minutes
The US medtech firm Hologic has bought the Finnish-French biotech Mobidiag for around €668M in the latest of a series of mergers, acquisitions, and stock market launches taking over the diagnostics market.
Hologic’s move is the latest in a flurry of activity from the women’s health specialist, which has snapped up Diagenode in Belgium, Biotheranostics in the US, and Somatex in Germany this year alone.
This is just one example of the many financial transactions happening in the diagnostics market over the past few months, with major deals, increasing stock prices, and unprecedented revenues.
(BIOC), (BMKDF) - 3 Cancer Diagnostic Stocks To Watch Following Roche s GenMark Buy benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Share:
Ark Funds hosted an investor webinar Tuesday, sharing ideas on several industries and portfolio components, including a discussion on some names in the genomics space.
Ark Funds On Genomics: Ark Funds is well-known for its bullish thesis on the genomics market. The company has the Ark Genomic Revolution ETF (BATS: ARKG), an ETF devoted to the growth of the segment.
Exact Sciences (NASDAQ: EXAS) was highlighted by Ark Funds analyst Simon Barnett.
The company has made a series of acquisitions that could help the company’s position in the market, he said.
“Incorporating it all together, Exact can broaden out their portfolio [and] determine market share.”